Comparative study of four SARS-CoV-2 Nucleic Acid Amplification Test (NAAT) platforms demonstrates that ID NOW performance is impaired substantially by patient and specimen type.


Journal

Diagnostic microbiology and infectious disease
ISSN: 1879-0070
Titre abrégé: Diagn Microbiol Infect Dis
Pays: United States
ID NLM: 8305899

Informations de publication

Date de publication:
Jan 2021
Historique:
received: 08 06 2020
revised: 26 08 2020
accepted: 29 08 2020
pubmed: 28 9 2020
medline: 19 12 2020
entrez: 27 9 2020
Statut: ppublish

Résumé

The COVID-19 pandemic in the United States created a unique situation where multiple molecular SARS-CoV-2 diagnostic assays rapidly received Emergency Use Authorization by the FDA and were validated by laboratories and utilized clinically, all within a period of a few weeks. We compared the performance of four of these assays that were evaluated for use at our institution: Abbott RealTime m2000 SARS-CoV-2 Assay, DiaSorin Simplexa COVID-19 Direct, Cepheid Xpert Xpress SARS-CoV-2, and Abbott ID NOW COVID-19. Nasopharyngeal and nasal specimens were collected from 88 ED and hospital-admitted patients and tested by the four methods in parallel to compare performance. ID NOW performance stood out as significantly worse than the other 3 assays despite demonstrating comparable analytic sensitivity. Further study determined that the use of a nasal swab compared to a nylon flocked nasopharyngeal swab, as well as use in a population chronically vs. acutely positive for SARS-CoV-2, were substantial factors.

Identifiants

pubmed: 32980807
pii: S0732-8893(20)30577-0
doi: 10.1016/j.diagmicrobio.2020.115200
pmc: PMC7470790
pii:
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

115200

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Références

J Clin Virol. 2020 Jul;128:104426
pubmed: 32417674
J Clin Virol. 2020 Jul;128:104429
pubmed: 32425657
Am J Clin Pathol. 2020 Jul 7;154(2):201-207
pubmed: 32462195
J Thorac Imaging. 2020 Jul;35(4):W105-W106
pubmed: 32404797
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32327448
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32332061
J Clin Virol. 2020 Jul;128:104428
pubmed: 32434706
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32341142
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32461287
J Clin Microbiol. 2020 Jul 23;58(8):
pubmed: 32303564

Auteurs

Paul R Lephart (PR)

Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA. Electronic address: plephart@umich.edu.

Michael A Bachman (MA)

Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.

William LeBar (W)

Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.

Scott McClellan (S)

Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.

Karen Barron (K)

Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.

Lee Schroeder (L)

Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.

Duane W Newton (DW)

Department of Pathology, University of Michigan Medical School, Ann Arbor, MI, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH